Kymera Therapeutics
biopharmaceutical company
KYMR Nasdaq
ISIN US5015751044 SEC CIK 1815442
Follow Kymera Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
−100% vs same quarter last year
Net income
−$132M
−60.6% vs same quarter last year
EPS, diluted
−$1.32
−40.4% vs same quarter last year
Operating cash flow
−$77.9M
−187.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Revenue |
|---|---|
| FY25 | $39.2M |
| FY24 | $47.1M |
| FY23 | $78.6M |
| FY22 | $46.8M |
| FY21 | $72.8M |
| FY20 | $34M |
| FY19 | $2.9M |
| FY18 | - |
- Gross margin
- Operating margin
Show the numbers
| Year | Gross margin | Operating margin |
|---|---|---|
| FY25 | 0% | −891.1% |
| FY24 | 0% | −555.8% |
| FY23 | 0% | −210.6% |
| FY22 | 0% | −344.4% |
| FY21 | - | −138% |
| FY20 | - | −136.1% |
| FY19 | - | −1438.5% |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$234.3M |
| FY24 | −$207.3M |
| FY23 | −$137.3M |
| FY22 | −$155.9M |
| FY21 | −$130.5M |
| FY20 | $79M |
| FY19 | $17.4M |
| FY18 | - |